Early fibrin biofilm development in cardiovascular infections

Safae Oukrich1, Jane Hong1, Mariël Leon-Grooters1

  • 1Biomedical Engineering, Department of Cardiology, Cardiovascular Institute, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.

Biofilm
|March 4, 2025
PubMed

Insights

Staphylococcus aureus uses coagulase to form fibrin biofilms, crucial for cardiovascular infections. This study reveals early fibrin formation mechanisms in S. aureus cardiovascular biofilms.

Area of Science:

  • Microbiology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Staphylococcus aureus is the primary cause of cardiovascular infections.
  • Coagulase production by S. aureus facilitates fibrinogen-to-fibrin conversion, aiding biofilm formation.
  • The early stages of fibrin formation in S. aureus cardiovascular biofilms are not well understood.

Purpose of the Study:

  • To investigate the early development of cardiovascular biofilms caused by Staphylococcus aureus.
  • To understand the role of coagulase in fibrin-based biofilm formation.
  • To analyze bacterial growth, metabolic activity, and fibrinogen utilization under various conditions.

Main Methods:

  • Culturing of clinical isolates (S. aureus, S. lugdunensis, S. aureus Δcoa) in different media (TSB, IMDM, human plasma) with or without porcine heart valves.
  • Measurement of bacterial growth, metabolic activity, and fibrinogen utilization over 24 hours.
  • Time-lapse confocal microscopy for visualizing biofilm development and fibrin network structure.

Main Results:

  • S. aureus showed enhanced growth in TSB and human plasma compared to S. lugdunensis and S. aureus Δcoa.
  • Peak metabolic activity was highest in TSB and lowest in human plasma, with variations influenced by porcine valves.
  • Confocal microscopy confirmed fibrin-based biofilm development exclusively in coagulase-producing S. aureus strains, with initial fibrin strands forming within 3 hours in human plasma.

Conclusions:

  • Fibrin formation, mediated by S. aureus coagulase, is a key early event in cardiovascular biofilm development.
  • Experimental conditions significantly impact bacterial behavior and biofilm formation.
  • This research provides critical insights into the pathogenesis of S. aureus cardiovascular infections.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.7K